GPX3 and gastric adenocarcinoma: GPX3 expression is significantly reduced in various tumor tissues, including breast cancer, colon adenocarcinoma, head–neck squamous-cell carcinoma, kidney renal clear-cell carcinoma, lung adenocarcinoma, and stomach adenocarcinoma, and it has good diagnostic accuracy (AUC > 0.75, up to 0.9), which is associated with higher stages and lymph node metastasis, as well as poorer prognosis.